FDA unveils second batch of commissioner voucher winnersnews2025-11-06T20:07:01+00:00November 6th, 2025|Endpoints News|
J&J’s Caplyta approved by FDA as add-on treatment for depressionnews2025-11-06T14:20:11+00:00November 6th, 2025|Endpoints News|
FDA reviewers were divided over Stealth’s data before Barth drug approvalnews2025-11-05T20:15:07+00:00November 5th, 2025|Endpoints News|
W&H Medical Unveils the Only FDA-Cleared Piezo & Drill Combo Console for Rhinoplasty and Facial Surgerynews2025-11-05T19:15:09+00:00November 5th, 2025|Medical Device News Magazine|
FDA rejects Biohaven’s ataxia drug, shutting down company’s second attempt to win approvalnews2025-11-05T16:39:16+00:00November 5th, 2025|Endpoints News|
Post-Hoc Live: M&A, FDA, MFN and more — with our cousins at the FTnews2025-11-04T12:00:13+00:00November 4th, 2025|Endpoints News|
Day after resigning, Tidmarsh now says he’ll fight exit from FDAnews2025-11-03T20:55:14+00:00November 3rd, 2025|Endpoints News|
UniQure’s Huntington’s gene therapy is delayed, as FDA suggests it may walk back accelerated approval blessingnews2025-11-03T13:34:28+00:00November 3rd, 2025|Endpoints News|
Tidmarsh’s exit at FDA pushes an agency in transition further toward instabilitynews2025-11-03T02:48:10+00:00November 3rd, 2025|Endpoints News|
FDA drug head Tidmarsh is put on leave, according to reportsnews2025-11-02T22:13:53+00:00November 2nd, 2025|Endpoints News|
